1. Aquiring the Evidence TEACH 2013 TRACK 1

2.  Therapy  Utility  Performance  Likelihood  Diagnosis  Utility  Performance  Likelihood  Prognosis  Utility  Performance  Likelihood  Harm  Utility  Performance  Likelihood LINKING QUESTIONS TO STUDY DESIGNS  RCT  COHORT  CROSS-SECTIONAL  CASE CONTROL

3.  THERAPY  Utility  Performance  Likelihood  DIAGNOSIS  Utility  Performance  Likelihood  PROGNOSIS  Utility  Performance  Likelihood  HARM  Utility  Performance  Likelihood LINKING QUESTIONS TO STUDY DESIGNS  THERAPY  RCT  Cohort  DIAGNOSIS  RCT  Cross-Sectional  Observational  PROGNOSIS  RCT  Cohort  Cohort/Single Arm  HARM  Cohort, Case-Control  Cohort  Cohort/Single Arm

4. LINKING STUDY DESIGNS TO SOURCES

5. EBM SEARCH ENGINES

6.  QUESTION 1  Therapy/Utility  P: Elderly patients with acute, stable AF, but no structural heart disease presenting to the ED < 48 hours of onset  I: Rapid acting pharmacological agents safely titrated to effect  C: Alternative regimens safely titrated to effect  O: Likelihood of rate control or cardioversion, hospital admission, complications of uncontrolled AF, adverse reactions to drugs BACK TO THE CASE Practice Guidelines, Systematic Review, RCT, Non-randomized studies

7.  QUESTION 2  Prognosis/Likelihood  P: Elderly patients with acute, stable AF, but no structural heart disease presenting to the ED < 48 hours of onset  I: Observation over a 30-day period  C: N/A  O: Stroke, decompensated heart failure, MI, death BACK TO THE CASE Practice Guidelines, Systematic Review, Cohort, Control Arm of an RCT

8.  QUESTION 3  Harm/Likelihood  P: Elderly patients with acute, stable AF, but no structural heart disease presenting to the ED < 48 hours of onset  I: Cardioversion in ED with discharge and early follow-up  C: N/A  O: Short-term complications of cardioversion, embolic events, admission, other complications of AF BACK TO THE CASE Practice Guidelines, Systematic Review, Cohort, Single-Arm Study

9.  SUMMARY: NGC, GIN Dynamed  SYNTHESIS: DARE QUESTION 1

10.  SYNTHESIS: Pubmed  SINGLE STUDY: Pubmed QUESTION 2

11. QUESTION 3  SUMMARY: NGC  SINGLE STUDY: Pubmed